Diagnosis, Treatment, and Management of COPD and Asthma: Advances in the 21st Century
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 4678
Special Issue Editor
Interests: COPD; asthma; interstitial pneumonia; patient-reported outcomes; quality of life; health status; respiratory medicine; computed tomography
Special Issue Information
Dear Colleagues,
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity globally, and is the third leading cause of death in the USA. Since many patients with COPD complain of dyspnoea and exertional intolerance, the condition has been one of the model diseases for measuring patient-reported outcomes (PROs), such as health-related quality of life. For instance, the Chronic Respiratory Disease Questionnaire (CRQ) was the first published disease-specific tool for measuring the quality of life around the world. On the other hand, although so far there have been plenty of clinical practice guidelines across the world, asthma guidelines were the origin of all of the medical guidelines. An asthma management plan was first published in 1989 by Southampton’s group and the Thoracic Society of Australia and New Zealand, followed by the Guidelines for the Diagnosis and Management of Asthma, established by the U.S. Department of Health and Human Services. As just described, chest physicians have been playing a leading role in addressing critical development issues of medicine. The purpose of this Special Issue, entitled “Diagnosis, Treatment, and Management of COPD and Asthma: Advances in the 21st Century”, is to share up-to-date information and include recent knowledge regarding COPD and asthma. I believe this would be the best opportunity to publish your excellent work. Articles such as original articles or reviews are welcome, but we do not accept case/brief reports. Topics include, but are not limited to, the following:
- Early COPD or late COPD.
- Blood eosinophil count as a biomarker.
- Asthma and COPD overlap.
- Single-inhaler or multiple-inhaler triple therapy.
- Definition of COPD exacerbation.
- Frequent exacerbators.
- Patient-reported outcomes.
- Health status or health-related quality of life.
- Dyspnoea measurement.
- Epidemiology of dyspnoea.
- Integrated care as well as COPD care bundles.
- Telemedicine and eHealth.
Dr. Koichi Nishimura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
